International Journal of Antimicrobial Agents
Volume 14, Issue 3 , Pages 181-191 , April 2000

Immunomodulatory agents for prophylaxis and therapy of infections

  • K.N Masihi

      Affiliations

    • Corresponding Author InformationTel.: +49-30-45472453; fax: +49-30-45472619

References 

  1. Anonymous. The World Health Report 1996. Geneva: WHO, 1997.
  2. Pinner RW, Teutsch SM, Simonsen L, Klug LA, Graber JM, Clarke MJ, et al.  Trends in infectious diseases mortality in the United States. J. Am. Med. Assoc. 1996;275:189–193
  3. Acar JF. Consequences of bacterial resistance to antibiotics in medical practice. Clin. Infect. Dis. 1997;24(Suppl. 1):17–18
  4. Masihi KN. Immunotherapy of microbial diseases. In:  Hadden JW,  Szentivanyi A editor. Immunopharmacology Reviews. Plenum: New York; 1996;p. 157–199
  5. Masihi KN. Cytokines and immunomodulators: promising therapeutic agents. Parasitol. Today. 1994;10:1–2
  6. Masihi KN, editor. Immunotherapy of Infections. New York: Marcel Dekker, 1994.
  7. Masihi KN, Lange W, editors. Immunotherapeutic Prospects of Infectious Diseases. Berlin: Springer-Verlag, 1990.
  8. Masihi KN, Lange W, editors. Immunomodulators and Nonspecific Host Defence Mechanisms Against Microbial Infections. Pergamon: Oxford, 1988.
  9. Masihi KN, editor. Special issue: First European Conference on Immunopharmacology. 26–29 May 1997, Berlin. Int J Immunopharmacol 1997;19:463–617.
  10. Labro MT. Antibacterial agents – phagocytes: new concepts for old in immunomodulation. Int. J. Antimicrob. Agents. 1998;10:11–21
  11. Stevens DL. Immune modulatory effects of antibiotics. Curr. Opin. Infect. Dis. 1996;9:165–169
  12. Murray PJ, Aldovini A, Young RA. Manipulation and potentiation of antimycobacterial immunity using recombinant Bacille Calmette–Guerin strains that secrete cytokines. Proc. Natl. Acad. Sci. USA. 1996;93:934–939
  13. Elmer GW, Surawicz CM, McFarland LV. Biotherapeutic agents – a neglected modality for the treatment and prevention of selected intestinal and vaginal infections. J. Am. Med. Assoc. 1996;275:870–876
  14. De Mattia D, Decandia P, Ferrante P, Pace D, Martire B, Ciccarelli M, et al.  Effectiveness of thymostimulin and study of lymphocyte-dependent antibacterial activity in children with recurrent respiratory infections. Immunopharmacol. Immunotoxicol. 1993;15:447–459
  15. Goldstein G, Conant MA, Beall G, Grossman HA, Galpin JE, Thick G, et al.  Safety and effcacy of thymopentin in zidovudine (AZT)-treated asymptomatic HIV-infected subjects with 200–500 CD4 cells/mm3: a double-blind placebo-controlled trial. J. Acq. Immun. Defic. Syn. 1995;8:279–288
  16. Garaci E, Rocchi G, Perroni L, Dgostini C, Soscia F, Grelli S, et al.  Combination treatment with zidovudine, thymosin alpha 1 and interferon-alpha in human immunodeficiency virus infection. Int. J. Clin. Lab. Res. 1994;24:23–28
  17. D'Agostini C, Palamara AT, Favalli C, Sivilia M, Febbraro G, Bue C, et al.  Efficacy of combination therapy with amantadine, thymosin al and a/b interferon in mice infected with influenza A virus. Int. J. Immunopharmacol. 1996;18:95–102
  18. Mutchnick MG, Ehrinpreis MN, Kinzie JL, Peleman RR. Prospectives on the treatment of chronic hepatitis B and chronic hepatitis C with thymic peptides and antiviral agents. Antiviral. Res. 1994;24:245–257
  19. Hadden JW, Ongradi J, Specter S, Nelson R, Sosa M, Monell C, et al.  Methyl inosine monophosphate: a potential immunotherapeutic for early human immunodeficiency virus (HIV) infection. Int. J. Immunopharmacol. 1992;14:555–563
  20. Caramia G, Clemente E, Solli R, Mei V, Cera R, Carnelli V, et al.  Efficacy and safety of pidotimod in the treatment of recurrent respiratory infections in children. Arzneimittel-Forschung. 1994;44:1480–1484
  21. De Simone C, Famularo G, Tzantzoglou S, Moretti S, Jirillo E. Inosine pranobex in the treatment of HIV infection: a review. Int. J. Immunopharmacol. 1991;13(Suppl. 1):19–27
  22. Azuma I, Otani T. Potentiation of host defense mechanism against infection by a cytokine inducer, an acyl-MDP derivative, MDP-Lys(L18) (romurtide) in mice and humans. Med. Res. Rev. 1994;14:401–414
  23. Khaitov RM, Pinegin BV, Butakov AA, Andronova TM. Immunotherapy of infectious postoperative complications with glucosaminylmuramyl dipeptide. In:  Masihi KN editors. Immunotherapy of Infections. Marcel Dekker: New York; 1994;p. 205–211
  24. Parant MA, Parant FJ, Le Contel C, Lefrancier P, Chedid L. MDP derivatives and resistance to bacterial infections in mice. Adv. Exp. Med. Biol. 1992;319:175–184
  25. Masihi KN, Lange W, Rohde-Schulz B, Chedid L. Muramyl dipeptide inhibits replication of human immunodeficiency virus in vitro. AIDS. Res. Human Retrovir. 1990;6:393–399
  26. Masihi KN, Rohde-Schulz B, Masek K, Palache B. Antiviral and adjuvant activity of immunomodulator adamantylamide dipeptide. Adv. Exp. Med. Biol. 1992;319:275286
  27. Masihi KN, Masek K. Effect of the synthetic immunomodulator adamantylamide dipeptide on replication of human immunodeficiency virus alone and in combination with azidothymidine. Int. J. Immunother. 1993;9:143–150
  28. Maeda YY, Yonekawa H, Chihara G. Application of lentinan as cytokine inducer and host defense potentiator in immunotherapy of infectious diseases. In:  Masihi KN editors. Immunotherapy of Infections. New York: Marcel Dekker; 1994;p. 261–279
  29. Babineau TJ, Marcello P, Swails W, Kenler A, Bistrian B, Forse RA. Randomized phase I/II trial of a macrophage-specific immunomodulator (PGG-glucan) in high-risk surgical patients. Ann. Surg. 1994;220:601–609
  30. Takeda-Hirokawa N, Neoh LP, Akimoto H, Kaneko H, Hishikawa T, Sekigawa I, et al.  Role of curdlan sulfate in the binding of HIV-1 gp120 to CD4 molecules and the production of gp120-mediated TNF-α. Microbiol. Immunol. 1997;41:741–745
  31. Masihi KN, Madaj K, Hintelmann H, Gast G, Kaneko Y. Down-regulation of tumor necrosis factor-alpha, moderate reduction of interleukin-1 beta, but not interleukin-6 or interleukin-10, by glucan immunomodulators curdlan sulfate and lentinan. Int. J. Immunopharmacol. 1997;19:463–468
  32. Nakane A, Minagawa T, Yasuda I, Yu C, Kato K. Prevention by gamma interferon of fatal infection with Listeria monocytogenes infection. Infect. Immunol. 1988;56:2011–2015
  33. Denis M. Growth of Listeria monocytogenes in murine macrophages and its modulation by cytokines, activation of bactericidal activity by interleukin-4 and interleukin-6. Can. J. Microbiol. 1991;37:253–257
  34. Leiby DA, Fortier AH, Crawford RM, Schreiber RD, Nacy CA. In vivo modulation of the murine immune response to Francisella tularensis LVS by administration of anticytokine antibodies. Infect. Immunol. 1992;60:84–89
  35. Subauste CS, Remington JS. Role of gamma interferon in Toxoplasma gondii infection. Eur. J. Clin. Microbiol. Infect. Dis. 1991;10:58–67
  36. Beck JM, Brunette EN, Fuchs HJ, Shellito JE, Debs RJ. Reduction in intensity of Pneumocystis carinii pneumonia in mice by aerosol administration of gamma interferon. Infect. Immunol. 1991;59:3859–3862
  37. Kumaratilake LM, Ferrante A, Rzepczyk C. The role of T Iymphocytes in immunity to Plasmodium falciparum. Enhancement of neutrophil-mediated parasite killing by lymphotoxin and IFN-gamma: comparisons with tumor necrosis factor effects. J. Immunol. 1991;146:762–767
  38. Williams DM, Byrne GI, Grubbs B, Marshal TJ, Schachter J. Role in vivo for gamma interferon in control of pneumonia caused by Clamydia trachomatis. Infect. Immunol. 1988;56:3004–3006
  39. Li H, Jerrells TR, Spitalny GL, Walker DH. Gamma interferon as a crucial host defense against Rikettsia conorii in vivo. Infect. Immunol. 1987;55:1252–1255
  40. Cano LE, Kashino SS, Arruda C, Andre D, Xidieh CF, Singer-Vermes LM, et al.  Protective role of gamma interferon in experimental pulmonary paracoccidioidomycosis. Infect. Immunol. 1998;66:800–806
  41. Way SS, Borczuk AC, Dominitz R, Goldberg MB. An essential role for gamma interferon in innate resistance to Shigella flexneri infection. Infect. Immunol. 1998;66:1342–1348
  42. Mestan J, Digl W, Mittnacht S, Hillen H, Blohm D, Moller A, et al.  Antiviral effects of recombinant tumor necrosis factor. Nature. 1986;323:816–819
  43. Merolla R, Rebert NA, Tsiviste PT, Hoffmann SP, Panuska JR. Respiratory syncytial virus replication in human lung epithelial cells: inhibition by tumor necrosis factor α and interferon β. Am. J. Respir. Crit. Care. Med. 1995;152:1358–1366
  44. Parant M. Effects of TNF in bacterial infections. Ann. Inst. Pasteur. Immunol. 1988;139:301–304
  45. Nakano Y, Onozuka K, Terada Y, Shinomiya H, Nakano M. Protective effect of recombinant tumor necrosis factor-alpha in murine salmonellosis. J. Immunol. 1990;144:1935–1941
  46. Roll JT, Young KM, Kurtz RS, Czuprynski CJ. Human rTNF alpha augments anti-bacterial resistance in mice: potentiation of its effects by recombinant human rIL-1 alpha. Immunology. 1990;69:316–322
  47. Bermudez LEM, Stevens P, Kolonoski P, Wu M, Young LS. Treatment of experimental disseminated Mycobacterium avium complex infection in mice with recombinant IL-2 and tumor necrosis factor. J. Immunol. 1989;143:2996–3000
  48. Suzuki K, Lee WJ, Hashimoto T, Tanaka E, Murayama T, Amitani R, et al.  Recombinant granulocyte-macropahge colony stimulating factor (GM-CSF) ot tumor necrosis factor-alpha (TNF-alpha) activate human alveolar macrophages to inhibit growth of Mycobacterium avium complex. Clin. Exp. Immunol. 1994;98:169–173
  49. Clark IA, Hunt NH, Butcher GA, Cowden WB. Inhibition of murine malaria (Plasmodium chabaudi) in vivo by recombinant interferon-gamma or tumor necrosis factor, and its enhancement by butylated hydroxyanisole. J. Immunol. 1987;139:34933496
  50. Liew FYC, Parkinson S, Millot A, Severn A, Carrier M. Tumor necrosis factor (TNF-alpha) in leishmaniasis. I. TNF-alpha mediates host protection against cutaneous leishmaniasis. Immunology. 1990;69:570–573
  51. Black CM, Israelski DM, Suzuki Y, Remington JS. Effect of recombinant tumor necrosis factor on acute infection in mice with Toxoplasma gondii or Trypanosoma cruzi. Immunology. 1989;68:570–574
  52. Lee M, Warren MK. CSF-1-induced resistance to viral infection in murine macrophages. J. Immunol. 1987;138:3019–3022
  53. Cheers C, Hill M, Haigh AM, Stanley ER. Stimulation of macrophage phagocytic but not bactericidal activity by colony-stimulating factor 1. Infect. Immunol. 1989;57:1512–1516
  54. Wang M, Friedman H, Djeu JY. Enhancement of human monocyte function against Candida albicans by colony-stimulating factors (CSF): IL-3, granulocytemacrophage-CSF, and macrophage-CSF. J. Immunol. 1989;143:671–677
  55. Mooney DP, Gameli RL, O’Reilly M, Herbert JC. Recombinant human granulocyte colony-stimulating factor and Pseudomonas burn wound sepsis. Arch. Surg. 1988;123:1353–1357
  56. Matsumoto M, Matsubara S, Matsuno T, Tamura M, Hattori K, Nomura H, et al.  Protective effect of human granulocyte colony-stimulating factor on microbial infection in neutropenic mice. Infect. Immunol. 1987;55:2715–2720
  57. Kullberg BJ, Netea MG, Curts JHAJ, Keuter M, Meis JFGM, Van der Meer JWM. Recombinant murine granulocyte colony-stimulating factor protects against acute disseminated Candida albicans infection in nonneutropenic mice. J. Infect. Dis. 1998;177:175–181
  58. Nielsen SD, Afzelius P, Dam-Larsen S, Nielsen C, Nielsen JO, Mathiesen L, et al.  Effect of granulocyte colony-stimulating factor (G-CSF) in human immunodeficiency virus-infected patients: Increase in numbers of naive CD4 cells and CD34 cells makes G-CSF a candidate for use in gene therapy or to support antiretroviral therapy. J. Infect. Dis. 1998;177:1733–1736
  59. Kemper CA, Bemmudez LE, Deresinski SC. Immunomodulatory treatment of Mycobacterium avium complex bacteremia in patients with AIDS by use of recombinant granulocyte-macrophage colony-stimulating factor. J. Infect. Dis. 1998;177:914–920
  60. Marodi L, Tournay C, Kaposzta R, Johnston RB, Moguilevsky N. Augmentation of human macrophage candidacidal capacity by recombinant human myeloperoxidase and granulocyte-macrophage colony-stimulating factor. Infect. Immunol. 1998;66:2750–2754
  61. Fontt EO, De Baetselier P, Heirman C, Thielemans K, Lucas R, Vray B. Effects of granulocyte-macrophage colony-stimulating factor and tumor necrosis factor alpha on Trypanosoma cruzi trypomastigotes. Infect. Immunol. 1998;66:2722–2727
  62. Shinomiya N, Tsuru S, Katsura Y, Kayashima S, Nomoto K. Enhanced resistance against Listeria monocytogenes achieved by pretreatment with granulocyte colony-stimulating factor. Infect. Immunol. 1991;59:4740–4743
  63. Morrissey PJ, Charrier K. GM-CSF administration augments the survival of ity-resistant A/J mice, but not ity-susceptible C57BL/6 mice, to a lethal challenge with Salmonella typhimurium. J. Immunol. 1990;144:557–561
  64. Williams MA, White SA, Miller JJ, Toner C, Withington S, Newland AC, et al.  Granulocyte-macrophage colony-stimulating factor induces activation and restores respiratory burst activity in monocytes from septic patients. J. Infect. Dis. 1998;177:107–115
  65. Czuprynski CJ, Brown JF. Recombinant murine interleukin-1 alpha enhancement of nonspecific antibacterial resistance. Infect. Immunol. 1987;55:2061–2065
  66. Ozaki Y, Ohashi T, Minami A, Nakamura SI. Enhanced resistance of mice to bacterial infection induced by recombinant human interleukin-1α. Infect. Immunol. 1987;55:1436–1440
  67. Zhan YF, Stanley ER, Cheers C. Prophylaxis or treatment of experimental brucellosis with interleukin-1. Infect. Immunol. 1991;59:1790–1794
  68. Morrissey PJ, Charrier K. Interleukin-1 administration to C3H/HeJ mice after but not prior to infection increases resistance to Salmonella typhimurium. Infect. Immunol. 1991;59:4729–4731
  69. Vogels MTE, Eling WMC, Otten A, Van der Meer JWM. Interleukin-1 (IL-1)induced resistance to bacterial infection: role of the type I IL-1 receptor. Antimicrob. Agents. Chemother. 1995;39:1744–1747
  70. Kullberg B, Van't Wout JW, Van Furth R. Role of granulocytes in increased host resistance to Candida albicans induced by recombinant interleukin-1. Infect. Immunol. 1990;58:3319–3324
  71. Zhou P, Sieve MC, Tewari RP, Seder RA. Interleukin-12 modulates the protective immune response in SCID mice infected with Histoplasma capsulatum. Infect. Immunol. 1997;65:936–942
  72. Gazzinelli RT, Hieny S, Wynn TA, Wolf S, Sher A. Interleukin 12 is required for the T-lymphocyte-independent induction of interferon gamma by an intracellular parasite and induces resistance in T-cell-deficient hosts. Proc. Natl. Acad. Sci. USA. 1993;90:6115–6119
  73. Murray HW. Endogenous interleukin-12 regulates acquired resistance in experimental visceral leishmaniasis. J. Infect. Dis. 1997;175:1477–1479
  74. Heinzel FP, Schoenhaut DM, Rerko RM, Rosser LE, Gately MK. Recombinant interleukin 12 cures mice infected with Leishmania major. J. Exp. Med. 1993;177:1505–1509
  75. Brieland JK, Remick DG, LeGendre ML, Engleberg NC, Fantone JC. In vivo regulation of replicative Legionella pneumophila lung infection by endogenous interleukin-12. Infect. Immunol. 1998;66:65–69
  76. Mohan K, Stevenson MM. Interleukin-12 corrects severe anemia during bloodstage Plasmodium chabaudi AS in susceptible A/J mice. Exp. Hematol. 1998;26:45–52
  77. Monteiro JM, Harvey C, Trinchieri G. Role of interleukin-12 in primary influenza virus infection. J. Virol. 1998;72:4825–4831
  78. Carr JA, Rogerson J, Mulqueen MJ, Roberts NA, Booth RF. Interleukin-12 exhibits potent antiviral activity in experimental herpesvirus infections. J. Virol. 1997;71:7799–7803
  79. Cavanaugh VJ, Guidotti LG, Chisari FV. Interleukin-12 inhibits hepatitis B virus replication in transgenic mice. J. Virol. 1997;71:3236–3243
  80. Komatsu T, Barna M, Reiss CS. Interleukin-12 promotes recovery from viral encephalitis. Viral. Immunol. 1997;10:35–47
  81. Bancroft AJ, McKenzie ANJ, Grencis RK. A critical role for IL-13 in resistance to intestinal nematode infection. J. Immunol. 1998;160:3453–3461
  82. Montaner LJ, Bailer RT, Gordon S. IL-13 acts on macrophages to block the completion of reverse transcription, inhibit virus production, and reduce virus infectivity. J. Leukoc. Biol. 1997;62:126–132
  83. Vazquez N, Walsh TJ, Friedman D, Chanock SJ, Lyman CA. Interleukin-15 augments superoxide production and microbicidal activity of human monocytes against Candida albicans. Infect. Immmunol. 1998;66:145–150
  84. Chehimi J, Marshall JD, Salvucci O, Frank I, Chehimi S, Kawecki S, et al.  IL-15 enhances immune functions during HIV infection. J. Immunol. 1997;158:5978–5987

PII: S0924-8579(99)00161-2

International Journal of Antimicrobial Agents
Volume 14, Issue 3 , Pages 181-191 , April 2000

Article Tools

* Image Usage & Resolution